Τίτλος:
A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: COVID-19 vaccines were efficacious and safe in clinical trials. We report nine events of acute pericarditis (AP) in eight patients following COVID-19 vaccination with BNT162b2 (6/9), AZD1222 (2/9) and mRNA-1273 (1/9). Methods: All patients were referred for AP temporally linked with COVID-19 vaccination. Chest pain was the most common clinical manifestation. Alternative etiologies were excluded upon thorough diagnostic work up. AP diagnosis was established according to ESC guidelines. Findings: Five events occurred after the first vaccine dose and four after the second. The mean age in this cohort was 65.8 ± 10.2 years and the men/women ratio 3/5. All events resolved without sequelae; two events were complicated by cardiac tamponade requiring emergent pericardial decompression. Hospitalization was required in four cases. Interpretation: Although causality cannot be firmly established, AP has emerged as a possible complication following COVID-19 vaccination. Further investigation is indispensable to fully characterize this new entity. © 2021 Elsevier Ltd
Συγγραφείς:
Lazaros, G.
Anastassopoulou, C.
Hatziantoniou, S.
Kalos, T.
Soulaidopoulos, S.
Lazarou, E.
Vlachopoulos, C.
Vassilopoulos, D.
Tsakris, A.
Tsioufis, C.
Εκδότης:
ELSEVIER SCIENCE LTD.
Λέξεις-κλειδιά:
ad26.cov2.s vaccine; comirnaty; elasomeran; vaxzevria; bnt 162 vaccine; ChAdOx1 COVID-19 vaccine, adult; aged; aging; Article; clinical article; cohort analysis; coronavirus disease 2019; disease course; drug safety; Europe; female; heart tamponade; hospitalization; human; male; middle aged; pericardial decompression; pericardial disease; pericarditis; practice guideline; sex ratio; thorax pain; United States; adverse event; pericarditis; vaccination, Aged; COVID-19; COVID-19 Vaccines; Europe; Female; Humans; Male; Middle Aged; Pericarditis; SARS-CoV-2; United States; Vaccination
DOI:
10.1016/j.vaccine.2021.09.078
